Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma.

Literature DB >> 27071455

Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma.

Guru Sonpavde¹, Joaquim Bellmunt².

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 27071455 DOI： 10.1038/nrurol.2016.69

Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432

× No keyword cloud information.

8 in total

1. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

Authors: Daniel P Petrylak; Scott T Tagawa; Manish Kohli; Andrea Eisen; Christina Canil; Srikala S Sridhar; Alexander Spira; Evan Y Yu; John M Burke; David Shaffer; Chong-Xian Pan; Jenny J Kim; Jeanny B Aragon-Ching; David I Quinn; Nicholas J Vogelzang; Shande Tang; Hui Zhang; Christopher T Cavanaugh; Ling Gao; John S Kauh; Richard A Walgren; Kim N Chi
Journal: J Clin Oncol Date: 2016-02-29 Impact factor: 44.544

2. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.

Authors: Guru Sonpavde; Gregory R Pond; Jonathan E Rosenberg; Dean F Bajorin; Toni K Choueiri; Andrea Necchi; Giuseppe Di Lorenzo; Joaquim Bellmunt
Journal: J Urol Date: 2015-08-17 Impact factor: 7.450

3. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).

Authors: Susanne Krege; Heidrun Rexer; Frank vom Dorp; Patrick de Geeter; Theodor Klotz; Margitte Retz; Axel Heidenreich; Michael Kühn; Joern Kamradt; Susan Feyerabend; Christian Wülfing; Stefan Zastrow; Peter Albers; Oliver Hakenberg; Jan Roigas; Martin Fenner; Hans Heinzer; Mark Schrader
Journal: BJU Int Date: 2014-03 Impact factor: 5.588

4. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

Authors: J A McCaffrey; S Hilton; M Mazumdar; S Sadan; W K Kelly; H I Scher; D F Bajorin
Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544

5. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Authors: Joaquim Bellmunt; Christine Théodore; Tomasz Demkov; Boris Komyakov; Lisa Sengelov; Gedske Daugaard; Armelle Caty; Joan Carles; Agnieszka Jagiello-Gruszfeld; Oleg Karyakin; François-Michel Delgado; Patrick Hurteloup; Eric Winquist; Nassim Morsli; Yacine Salhi; Stéphane Culine; Hans von der Maase
Journal: J Clin Oncol Date: 2009-08-17 Impact factor: 44.544

6. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

Authors: Neeraj Agarwal; Joaquim Bellmunt; Benjamin L Maughan; Kenneth M Boucher; Toni K Choueiri; Angela Q Qu; Nicholas J Vogelzang; Ronan Fougeray; Guenter Niegisch; Peter Albers; Yu-Ning Wong; Yoo-Joung Ko; Srikala S Sridhar; Srinivas K Tantravahi; Matthew D Galsky; Daniel P Petrylak; Ulka N Vaishampayan; Amitkumar N Mehta; Tomasz M Beer; Cora N Sternberg; Jonathan E Rosenberg; Guru Sonpavde
Journal: Clin Genitourin Cancer Date: 2013-09-28 Impact factor: 2.872

7. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.

Authors: Petros D Grivas; Stephanie Daignault; Scott T Tagawa; David M Nanus; Walter M Stadler; Robert Dreicer; Manish Kohli; Daniel P Petrylak; David J Vaughn; Kathryn A Bylow; Steven G Wong; Joseph L Sottnik; Evan T Keller; Mahmoud Al-Hawary; David C Smith; Maha Hussain
Journal: Cancer Date: 2013-11-18 Impact factor: 6.860

8. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

Authors: Toni K Choueiri; Robert W Ross; Susanna Jacobus; Ulka Vaishampayan; Evan Y Yu; David I Quinn; Noah M Hahn; Thomas E Hutson; Guru Sonpavde; Stephanie C Morrissey; Geoffrey C Buckle; William Y Kim; Daniel P Petrylak; Christopher W Ryan; Mario A Eisenberger; Amir Mortazavi; Glenn J Bubley; Mary-Ellen Taplin; Jonathan E Rosenberg; Philip W Kantoff
Journal: J Clin Oncol Date: 2011-12-19 Impact factor: 44.544

8 in total

7 in total

Review 1. What Genetics Can Do for Oncological Imaging: A Systematic Review of the Genetic Validation Data Used in Radiomics Studies.

Authors: Rebeca Mirón Mombiela; Anne Rix Arildskov; Frederik Jager Bruun; Lotte Harries Hasselbalch; Kristine Bærentz Holst; Sine Hvid Rasmussen; Consuelo Borrás
Journal: Int J Mol Sci Date: 2022-06-10 Impact factor: 6.208

2. Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.

Authors: Claudia Ceci; Lucio Tentori; Maria Grazia Atzori; Pedro M Lacal; Elena Bonanno; Manuel Scimeca; Rosella Cicconi; Maurizio Mattei; Maria Gabriella de Martino; Giuseppe Vespasiani; Roberto Miano; Grazia Graziani
Journal: Nutrients Date: 2016-11-22 Impact factor: 5.717

Review 3. Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet.

Authors: Victor G Martinez; Ester Munera-Maravilla; Alejandra Bernardini; Carolina Rubio; Cristian Suarez-Cabrera; Cristina Segovia; Iris Lodewijk; Marta Dueñas; Mónica Martínez-Fernández; Jesus Maria Paramio
Journal: Front Genet Date: 2019-11-18 Impact factor: 4.599

Review 4. The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.

Authors: Chunping Cai; Xiaoji Wang; Qiurong Fu; Ai Chen
Journal: World J Surg Oncol Date: 2022-02-21 Impact factor: 2.754